


# Salazopyrin ad infinitum!



**“It is concluded that maintenance treatment of ulcerative colitis with sulphasalazine (salazopyrin) should be continued indefinitely unless contraindicated by side effects.”<sup>1</sup>**

The results of the above controlled trial carried out at the Nuffield Department of Clinical Medicine, Radcliffe Infirmary, Oxford are all the more welcome as earlier trials of cortisone<sup>2</sup> and prednisone<sup>3</sup> at standard dosages have shown them to be ineffective in reducing the number of recurrences of ulcerative colitis.

“Fortunately, Sulphasalazine tablets, 0.5 grams 4 times a day will prevent relapses in the majority


of patients with colitis, and only a few patients cannot tolerate this relatively small dose, which can be continued indefinitely since we do not know when, if ever, it can be safely stopped”.<sup>4</sup>

Salazopyrin (sulphasazine) is available as the plain 0.5g. tablet, 0.5g. EN-tab and as an 0.5g. suppository.

Literature and detailed information on Salazopyrin are available on request.

“The patients who received dummy tablets had more than four times the relapse rate of those receiving sulphasalazine”.<sup>1</sup> (Salazopyrin).

Salazopyrin is a registered trade mark.



Both groups of patients had been satisfactorily maintained for 1-5 years on Salazopyrin prior to the study, in which they took Salazopyrin or placebo for 6 months.

1. Gut (1973) 14 923 - 926
2. Brit. med. J. (1959) 1 387 - 394
3. Lancet (1965) 1 188 - 189
4. General Practitioner (1972) April 7 p 11

Further information on request from:-  
Pharmacia (Great Britain) Ltd.  
Paramount House,  
75 Uxbridge Road,  
London W5 5SS.  
Telephone: 01-579 0102/7



# Alternative dosage regimen of Caved-S produces impressive results in chronic duodenal ulcer

Endoscopic examination proved chronic duodenal ulceration in 32 male patients, whose clinical histories ranged from 2 to 30 years.<sup>1</sup>

## ADEQUATE DOSAGE

2 Caved-S tablets 5 times daily for up to 24 weeks

"... the daily dose selected was the median of that advised in a series of patients treated with deglycyrrhizinized liquorice tablets who had failed to respond to other measures and had been referred for surgery..."<sup>1</sup>

## THOROUGH CHEWING OF THE TABLETS

mixed Caved-S with the saliva appears to play an important role.

"Saliva may have a role of its own or a synergistic action with constituent of the liquorice extract. Work in India (Malhotra *et al*, 1965) has suggested that eating foods which do not require chewing results in an increased incidence of duodenal ulceration and that saliva exerts a protective action in peptic ulceration (Malhotra 1967; Malhotra, 1967)."<sup>1</sup>

## SWALLOWING ON AN EMPTY STOMACH

allows the bolus of Caved-S and saliva to reach the prepyloric area of the stomach, where maximum demulcent effect and healing occur.

"The advice that the agent should be taken on an empty stomach in the ambulant patient could be crucial. Simple studies on patients presenting for barium-meal examination have shown that if a small sip of barium is taken while in an upright position when the stomach is empty the bolus of barium rapidly travels down the lesser curve of the stomach and comes to rest in the prepyloric region. This may effectively produce a 'positioned release' preparation, and the bolus of mixed saliva and deglycyrrhizinized liquorice would appear to be strategically placed to exert maximum demulcent or healing effect."<sup>1</sup>

## RESULTS

Endoscopic examination showed that Caved-S had healed the ulceration in ALL 32 patients and in most the mucosa appeared normal.

<sup>1</sup>A Retrospective Endoscopic Survey of 32 patients. *The Practitioner*, (1975).

Further information is available on request.


**Tillotts Laboratories, Unit 24,  
Henlow Trading Estate, Henlow, Beds.**

# The convenient, disposable soft-tissue biopsy system that gets you the sample you need.

The only completely disposable needle/syringe designed specifically for soft-tissue aspiration biopsies.

The *Jamshidi soft-tissue Biopsy Needle/Syringe* is the complete, ready-to-use biopsy device in one package. Use it once and throw it away, with no danger of cross-infection.

Available in a wide range of needle gauge sizes, the needle/syringe is also available in the completely disposable *Kormed soft-tissue Biopsy Tray*, which contains everything you need for the biopsy procedure — neatly organized for maximum convenience and efficiency.



**1** The syringe's *locking plunger design* eliminates the need for maintaining syringe vacuum manually, thereby freeing the hands for better directional control.

**2** The unique, *permanently attached blocking device* prevents the sample from entering the syringe, adds rigidity to the needle for increased safety, and has a pointed tip for use with multi-dose ampules.

#### Sizes Available:

Gauge	Diameter	Length	Gauge	Diameter	Length
17	1.4mm	100mm	19	1.0mm	70mm
16	1.6mm	100mm	18	1.2mm	70mm
15	1.9mm	100mm	17	1.4mm	70mm
			16	1.6mm	70mm
			15	1.9mm	70mm

**3** Kormed's *exclusive tapered needle tip* is an important aid in securing proper samples, since it eliminates needle plugging and tissue fragmentation.



**Kormed, Inc.**

JAMSHIDI BIOPSY DEVICES  
2950 Metro Drive  
Minneapolis, Minnesota 55420  
(612) 854-0300

The Victorian Hospitals Assoc.  
P.O. Box 185  
Carlton South  
Victoria 3003  
Australia  
Tel. 419 1486

Lameris Instrumenten B.V.  
Biltstraat 149  
P.O.B. 2303  
Utrecht  
Holland  
Tel. 030 33 50 33

McGaw Ethicals, Ltd.  
P.O. Box 18-069  
236 Aprana Avenue  
Glen Innes  
Auckland  
New Zealand  
Tel. 588-036

Arnold R. Horwell, Limited  
2 Grangeway Kilburn High Road  
London NW5 2BP  
England  
Tel. 01-328 1551

**In haemorrhoids Fybogel complements topical therapy,** by raising the level of natural fibre in the diet.

Fybogel produces softer, well-formed stools. And that reduces straining—a principal cause of haemorrhoids. By complementing topical therapy Fybogel helps to provide a complete treatment for haemorrhoids.

# Strain remover



Fybogel: sachets containing 3.5g Ispaghula Husk BPC. Full prescribing information available on request from: Reckitt & Colman Pharmaceutical Division, Hull, HU8 7DS  
Fybogel is a registered trademark. PL No. 0044/0041

0001

# REVISTA ESPAÑOLA DE LAS ENFERMEDADES DEL APARATO DIGESTIVO

(Spanish Journal of the Diseases of the  
Digestive System)

Londres, 41. MADRID—28. (Spain)

A careful selection of papers, the collaboration of some of the most prestigious Doctors of the Speciality and the careful edition of every issue make this publication one of the best in Spain.

The following data give an idea of the volume and rhythm of edition of this Journal:

Number of pages on scientific and informative text:

In the year 1967,	1320 pages	and 590 figures
„ „ „ 1968,	1544	„ „ 666 „
„ „ „ 1969,	1566	„ „ 660 „
„ „ „ 1970,	2352	„ „ 864 „
„ „ „ 1971,	1446	„ „ 1148 „
„ „ „ 1972,	1562	„ „ 1046 „
„ „ „ 1973,	2434	„ „ 1137 „
„ „ „ 1974,	2272	„ „ 1047 „
„ „ „ 1975,	1412	„ „ 523 „

If you subscribe to REVISTA ESPAÑOLA DE LAS ENFERMEDADES DEL APARATO DIGESTIVO you will be always informed of the progress made in the speciality because it provides:

- Experimental scientific information
- Resolution of cases
- Prestige for your library

It will keep you up to date in the speciality and in the professional movement of gastroenterologists and pathologists.

You will be also informed of all the Congresses, Meetings, Courses, etc.

Ask for a sample copy.

Price for annual subscription: \$ USA 30 (20 issues)